Language selection


What We Heard: Summary of Canada's consultation on biomanufacturing capacity

From: Innovation, Science and Economic Development Canada

On this page

The consultation

From the outset of the COVID-19 pandemic, the Government of Canada has demonstrated strong and decisive action to combat the virus and mitigate its economic and health impacts on Canadians while supporting Canadian workers and businesses.

The Government of Canada is equally resolved to ensure that Canada is well-positioned to respond to future health emergencies and is committed to promote the long-term sustainable growth in Canada's biomanufacturing sector. Budget 2021 illustrates this commitment by investing a total of $2.2 billion over seven years towards growing a vibrant domestic biomanufacturing and life sciences sector. These investments will help build Canada's talent pipeline and research system, and support the growth of Canadian life sciences firms.

Key findings

In February and March 2021, Innovation, Science and Economic Development Canada (ISED), in collaboration with Health Canada and the Public Health Agency of Canada, and with the assistance of the COVID‑19 Vaccine Task Force, engaged expert stakeholders in a series of virtual roundtables as well as by soliciting written submissions on the long-term elements of a robust domestic biomanufacturing sector. A detailed consultation paper entitled, Considering the Creation of New Biomanufacturing Capacity for Canada, laid out a series of considerations and key questions.

Consultation key findings include emphasis on:

The full report

The Government of Canada is carefully considering the feedback we received through the consultation as we plan for a strong new generation of biologics manufacturing and life sciences in Canada.

We invite you to read the full "What We Heard" report.

Date modified: